Welcome to our dedicated page for Septerna news (Ticker: SEPN), a resource for investors and traders seeking the latest updates and insights on Septerna stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Septerna's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Septerna's position in the market.
Septerna, a clinical-stage biotech company focused on GPCR-targeted drug discovery, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. Jeffrey Finer, M.D., Ph.D., the company's CEO and co-founder, will deliver a presentation on Tuesday, January 14, 2025, at 3:45 p.m. PT in San Francisco. The presentation will be accessible via live webcast through Septerna's website and will remain available for 30 days afterward.
Septerna (SEPN) reported Q3 2024 financial results and business updates. The company recently initiated Phase 1 clinical trials for SEP-786, an oral treatment for hypoparathyroidism, with data expected in mid-2025. Following a successful IPO raising $302.6 million, Septerna has a strong cash position of $137.5 million as of September 30, 2024, expected to fund operations into H2 2027. Q3 financial results showed R&D expenses of $17.8 million, G&A expenses of $4.9 million, and a net loss of $20.5 million. The company is advancing multiple GPCR-targeted programs in endocrinology, immunology, inflammation, and metabolic diseases.
Septerna (Nasdaq: SEPN) has successfully completed its upsized initial public offering, raising $331.2 million in gross proceeds. The clinical-stage biotechnology company, focused on GPCR oral small molecule drug discovery, sold 18,400,000 shares at $18.00 per share, including 2,400,000 additional shares from the full exercise of underwriters' option. Trading began on the Nasdaq Global Market on October 25, 2024, under ticker SEPN. J.P. Morgan, TD Cowen, Cantor, and Wells Fargo Securities served as joint bookrunners for the offering.
Septerna (Nasdaq: SEPN) has announced the pricing of its upsized initial public offering of 16,000,000 shares at $18.00 per share. The company has granted underwriters a 30-day option to purchase up to an additional 2,400,000 shares. Trading is expected to begin on the Nasdaq Global Market on October 25, 2024. The IPO's gross proceeds are anticipated to reach $288.0 million, before deducting underwriting discounts and commissions. The offering is expected to close on October 28, 2024, with J.P. Morgan, TD Cowen, Cantor, and Wells Fargo Securities serving as joint bookrunners.
FAQ
What is the current stock price of Septerna (SEPN)?
What is the market cap of Septerna (SEPN)?
